皮肤上生长因子受体抑制剂用于肺癌和角质炎风险
Pin-Chia Huang1, Ching-Chieh Lin2, Reza Dana3
1Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
皮表皮生长因子受体抑制剂 (EGFRis) 会增加肺癌患者的角质炎风险. 第二代EGFRi的阿法替尼显示出更高的风险,强调需要进行眼部监测.
科学领域:
- 在瘤学瘤学.
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 表皮生长因子受体抑制剂 (EGFRis) 与眼部副作用有关.
- 关于EGFRi治疗与角质炎之间的具体联系的证据有限.
- 了解这种关联对于接受EGFRi治疗的肺癌患者的管理至关重要.
研究的目的:
- 研究表皮生长因子受体抑制剂 (EGFRi) 治疗与肺癌患者新发角膜炎风险之间的关联.
- 为了确定与状炎风险增加相关的特定EGFRi病原体.
主要方法:
- 一项基于美国人口的队列研究,利用TrinetX数据从2003年5月到2023年10月.
- 分析包括使用EGFRis或不使用EGFRis (gefitinib,erlotinib,afatinib,osimertinib) 治疗的肺癌患者.
- 后勤和考克斯比例危险回归模型被用来确定新发性角膜炎的风险.
主要成果:
- 与非暴露患者相比,接受EGFRis治疗的患者患角质炎的风险高1.52倍.
- 与EGFRi相关的角膜炎亚型包括角膜结膜炎 (HR 1.37),表面角膜炎 (HR 1.64) 和角膜 (HR 2.13).
- 亚法替尼 (第二代EGFRi) 与明显更高的角质炎风险相关 (HR 2.23).
结论:
- 肺癌患者的EGFRi治疗与新发性角质炎的风险增加有关.
- 第二代EGFRi阿法替尼具有特别高的风险.
- 眼部并发症的及时诊断和管理对于预防不良结果和治疗中断至关重要.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Mitogens and the Cell Cycle
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
